<DOC>
	<DOC>NCT02874586</DOC>
	<brief_summary>An open-label,pilot study to evaluate the efficacy and safety of plasma exchange combination of immunosuppressive regimens, for the remission of autoimmune hepatitis (AIH).</brief_summary>
	<brief_title>Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Autoimmune</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Diagnosed with autoimmune hepatitis based on liver biopsy results, with the indications of immunosuppressive therapy; High levels of total bilirubin (TB) (≥10 X ULN); High levels of immunoglobulin G(IgG) (≥1.5 X ULN); Agreed to participate in the trial, and assigned informed consent; The presence of hepatitis A, B, C, D, or E virus infection; Patients with presence of liver cirrhosis or portal hypertension; Primary sclerosing cholangitis, nonalcoholic steatohepatitis, drug induced liver disease or Wilson disease confirmed by liver biopsy; Pregnant and breeding women; Patients with severe anemia (hemoglobin &lt; 8 g/dL), leukopenia (WBC &lt; 2500/mm3), or thrombocytopenia (platelet count &lt; 50,000/mm3); Severe disorders of other vital organs, such as severe heart failure, cancer; Parenteral administration of blood or blood products within 6 months before screening; Recent treatment with drugs having known liver toxicity; Taken part in other clinic trials within 6 months before screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>